Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 7Lung Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma 1Platinum-Resistant Lung Small Cell Carcinoma 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Malignancies 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Advanced Solid Tumors 1Adenoma, Islet Cell 1

Interventions

pegfilgrastim 13Filgrastim 13Cytarabine 5Cyclophosphamide 5pegylated granulocyte colony-stimulating factor 4Etoposide 4Methotrexate 3Doxorubicin 3Docetaxel 3trifluridine tipiracil drug combination 2Vincristine 2Daunorubicin 2Cisplatin 2Amifostine 2trilaciclib 1niraparib 1lintuzumab 1leridistim 1isavuconazole 1fludarabine phosphate 1fish oil triglycerides 1etoposide phosphate 1eravacycline 1eflapegrastim 1angiotensin I (1-7) 1Voriconazole 1Vegetables 1Topotecan 1Thioguanine 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neutropenia × PM 01183 × Clear all
NCT05578326 2026-03-30

Study of Trilaciclib and Lurbinectidin

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
30 enrolled
Thoracic

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡